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a b s t r a c t
Acute appendicitis in children with acute leukemia is uncommon and often recognized late. Immuno-
compromised host state coupled with the importance of avoiding treatment delays makes management
additionally challenging. Leukemic inﬁltration of the appendix though rare must also be considered.
Although successful conservative management has been reported, surgical intervention is required in
most cases. We present our experience with acute appendicitis in children with acute leukemia and a
case of complete remission of acute myeloid leukemia with a short course of decitabine. Decitabine may
serve as bridging therapy in critically ill patients who are unable to undergo intensive chemotherapy.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Acute appendicitis and typhlitis are the most common causes
of gastrointestinal surgical complications in children undergoing
chemotherapy for acute leukemia with reported incidences of 0.5–
4.4% and 1.7–6.7% respectively [1–4]. Early diagnosis by radiologic
imaging is essential as appendicitis usually requires emergent
surgical management. Appendicitis with leukemic inﬁltration as
the initial presenting feature may also rarely occur [5,6]. In such
situations, the clinician must also balance the risk of further
immunosuppression and chemotherapeutic toxicities with the risk
of delaying appropriate leukemia therapy.
2. Case series
A retrospective case review of all children r18 years of age
diagnosed with acute leukemia at our institution between January
2002 and December 2011 was performed after obtaining institu-
tional IRB approval. Amongst 154 children eligible, three (1.9%)
patients were diagnosed with appendicitis (Table 1). Appendicitis
was diagnosed based on clinical, imaging and histologic ﬁndings.
2.1. Case 1
A 17-year-old girl with relapsed acute myeloid leukemia (AML)
developed nausea, vomiting, mild lower abdominal pain and
breakthrough menstrual bleeding three days into hospitalization
for induction chemotherapy with cytarabine and mitoxantrone. On
day ﬁfteen, her abdominal pain localized to the right lower
quadrant (RLQ) followed by fevers three days later. Abdominal
CT scan demonstrated a thickened appendix with inﬂammation in
the periappendiceal fat planes.
An emergent open appendectomy was performed. Pathology
showed acute appendicitis without perforation or leukemic inﬁl-
tration. Peri-operatively, absolute neutrophils were too few to
count. Blood cultures were negative. She received broad-spectrum
antimicrobial therapy and chemotherapy was resumed without
delay. Eventually, she underwent a matched unrelated donor bone
marrow transplant (BMT) and was in remission at seven-year
follow-up.
2.2. Case 2
An 18-year-old girl with relapsed leukemia consistent with
acute lymphoblastic leukemia (ALL) was hospitalized for che-
motherapy with cytarabine and clofarabine. In addition to inter-
mittent nausea, vomiting, and diarrhea, signiﬁcant RLQ pain with
fever on hospital day nineteen (maximum 39.5 1C) prompted an
abdominal CT scan that showed an edematous, thickened appendix
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with surrounding inﬂammation. She underwent an emergent laparo-
scopic appendectomy and pathology revealed a non-perforated appe-
ndix with inﬂammatory inﬁltrate without leukemic involvement. She
had too few neutrophils to count. Broad-spectrum antimicrobial cove-
rage was initiated for Escherichia coli bacteremia. Chemotherapy was
resumed three weeks following surgery. She eventually underwent
a matched related donor BMT and was in remission at three-year
follow-up.
2.3. Case 3
A 10-year-old girl presented with generalized myalgias, fevers and
gingival hypertrophy and was diagnosed with primary AML with
maturation (FAB: M2). Cytogenetics revealed no clonal abnormalities
and AML panel ﬂuorescent in-situ hybridization studies were normal.
During hospitalization for induction chemotherapy, after ﬁve days of
decitabine (20 mg/m2/day) on study and one dose of systemic
cytarabine (100 mg/m2/dose), she developed abdominal pain with
high-grade fevers (maximum 40.1 1C). Abdominal CT scan demon-
strated numerous ﬂuid-ﬁlled edematous bowel loops with enhance-
ment, ﬂuid collections, and ﬁndings consistent with an inﬂamed
appendix with fecalith. An emergent laparotomy revealed gross
soilage of the abdomen due to a perforated necrotic appendix
eroding into the distal ileum and colon necessitating a diverting
ileostomy and partial right colectomy. At the time of surgery, her
absolute neutrophil count (ANC) was 4.08109/L.
Histopathology revealed immature myeloid cells, consistent with
leukemic involvement of the appendix, in addition to inﬂammatory
inﬁltrates. Postoperative course was complicated by abdominal
abscesses with E. coli and vancomycin resistant Enterococcus. Par-
enteral antimicrobial therapy was continued for approximately
6 weeks during which chemotherapy was held to avoid further
immunosuppression. Packed red blood cell and platelet transfusions
were required within the ﬁrst postoperative week following which
no transfusion support was needed until resumption of standard
chemotherapy about 8 weeks later. During this 8 week period, her
ANC ﬂuctuated from 0.64 to 5.33109/L with counts of o1109/L
noted only on 2 occasions at 24 days and 37 days from surgery. She
did not experience sustained neutropenia and, hence, no signiﬁcant
issues were noted during this 8 week period.
Bone marrow biopsy twenty-ﬁve days from initiation of induction
chemotherapy showed no morphologic features of AML. Despite
receiving only a short course of decitabine and one dose of systemic
cytarabine, she achieved and maintained complete remission until
resumption of standard intensive chemotherapy. She remains in
remission 2.5 years following completion of therapy.
3. Discussion
Appendicitis is seen in the general population with a lifetime
cumulative incidence rate of 9% [7]. Our calculated incidence rate
of appendicitis in the setting of acute leukemia (1.9%) correlates
with the reported incidence of 0.5–4.4% [1]. Leukemic involvement
of the gastrointestinal tract as well as the treatment thereof can
compromise the structural integrity of the intestinal wall [5].
Moreover, atypical presentations of appendicitis are common in
immunocompromised patients due to underlying malignancy and
ongoing chemotherapy. Early symptoms such as nausea, vomiting,
abdominal pain, and diarrhea are non-speciﬁc and may be
attributed to chemotherapy side effects delaying accurate diag-
nosis [8]. In addition, typhlitis often mimics the classic presenta-
tion of appendicitis, and therefore imaging must be performed to
distinguish these entities as their management approaches differ.
Although successful conservative management has been
reported [9], the majority require surgical intervention to avoid
devastating complications [1,10]. Several groups have demon-
strated safety and efﬁcacy of surgical intervention [1,4,10] and
operative management may also shorten the length of hospital
stay compared to nonoperative management [10]. In our cohort, all
three patients were operated upon emergently and all of them
including the patient with appendiceal perforation and leukemic
inﬁltration tolerated surgery well.
For the treating clinician, the bigger conundrum is the need to
suspend chemotherapeutic treatment during life-threatening
infections such as appendicitis, while weighing in a heightened
risk for uncontrolled leukemic cell proliferation. Alternatively,
other anti-leukemic agents such as decitabine have been demon-
strated to be effective and well-tolerated in adults with myelo-
dysplastic syndrome, high risk AML, as well as those ineligible for
standard chemotherapy due to extensive comorbidities such as the
elderly [11–13].
Decitabine (5-aza-20-deoxycytidine) is a cytosine nucleoside
analog that after phosphorylation directly incorporates into DNA
resulting in inhibition of DNA methyltransferases. The resulting
DNA hypomethylation causes reversal of abnormal epigenetic
silencing of genes critical to normal cellular differentiation, pro-
liferation, and normal cellular life processes such as apoptosis [14].
It has minimal toxicity and hence is favored in patients who are
unable to tolerate standard chemotherapeutic regimens [11].
Our third patient was enrolled in a trial utilizing a short ﬁve-
day course of decitabine prior to intensive chemotherapy with
cytarabine, daunorubicin and etoposide. She achieved and
remained in remission with one cycle of decitabine and one dose
of cytarabine without signiﬁcant hematologic toxicities despite
considerable delay in resumption of chemotherapy due to over-
whelming infection. Low-dose decitabine (20 mg/m2/day for 10
days given every 4 weeks) has demonstrated promising results in
children with very high risk relapsed/ refractory AML in whom
other treatment options had been exhausted. Three out of eight
patients had a complete response, with best responses noted after
a median of 2.5 cycles. Despite signiﬁcant comorbidities, decita-
bine monotherapy demonstrated minimal toxicity [15]. Recently,
sequential treatment with decitabine and cytarabine was found to
be more effective than cytarabine alone in xenograft models of
childhood AML [16].
Table 1
Patient characteristics.
Case Age (years)/
gender
Diagnosis (newly diagnosed/
relapse)
Management of appendicitis Leukemic inﬁltration of the
appendix
Peri-operative issues ANC at surgery
(x109/L)
1 17/F AML (relapse) Open appendectomy No None 0a
2 18/F ALL (relapse) Laparoscopic appendectomy No Escherichia coli
bacteremia
0a
3 10/F AML (newly diagnosed) Open appendectomy, right
ileocolectomy
Yes Multiple abdominal
abscesses
4.08
F, female; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; ANC, absolute neutrophil count.
a Too few cells to count.
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Relative to studies with heavily pre-treated patients, our patient
was chemotherapy naive and had minimal hematologic or other
toxicities secondary to chemotherapy. Given the favorable toxicity
proﬁle and efﬁcacy in childhood AML, we suggest that decitabine
may serve as a bridging anti-leukemic agent during serious illness
and reduce risk of recurrence secondary to prolonged treatment
delays. Overall, managing concurrent malignancy and critical illness
is a delicate balance, one in which decitabine may play a pivotal
role; however further clinical trials are needed.
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